Inspire Plans Intranasal Epinastine Trials Following Licensing Deal With Boehringer Ingelheim
This article was originally published in The Pink Sheet Daily
The intranasal product will join ophthalmic epinastine (Elestat), which Inspire promotes with partner Allergan.
You may also be interested in...
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.
The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.
The company has inked a hospital supply contract for the anesthetic droperidol.